March 21, 2016 — Circle Cardiovascular Inc., developer of cardiac magnetic resonance (MR) and computed tomography (CT) ...

The use of novel oral anticoagulants (NOACs) will see a substantial rise after an initially sluggish uptake and will start to be elected over warfarin, according to an analyst with research and consulting firm GlobalData. Warfarin is the current standard-of-care product in certain indications.

CorMatrix Cardiovascular Inc. announced treatment of the first patient to receive their tissue-engineered regenerative CorMatrix ECM (Extracellular Matrix) Tricuspid Valve. The operation was performed by Marc Gerdisch, M.D., FACS, FACC, chief of cardiovascular and thoracic surgery at Franciscan St. Francis Health in Indianapolis.

Nearly half of all atrial fibrillation (AF) patients at the highest risk for stroke are not being prescribed blood thinners by their cardiologists, according to a new study.

Boston Scientific announced in late February that the Eluvia Drug-Eluting Vascular Stent System received CE Mark, and is commencing commercialization immediately in the European Union and other countries where CE Mark is recognized.

A recent study is bringing new hope to families of children who struggle with a common form of leukemia and thus must confront an elevated risk for long-term heart ailments caused by chemotherapy.

Bioengineers and physicians at the University of California, San Diego have developed a potential new therapy for critical limb ischemia, a condition that causes extremely poor circulation in the limbs. The new therapy could prevent or limit amputations for a condition that affects more than 27 million people and is a manifestation of advanced peripheral arterial disease.